Henry Ji, Sorrento CEO (Scilex Pharmaceuticals)
May 19, 2020 11:11 AM EDTUpdated May 20, 07:25 AM
R&D
Coronavirus

How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

Jason Mast

Editor

Last week, a Cal­i­for­nia biotech called Sor­ren­to Ther­a­peu­tics emailed re­porters about the dis­cov­ery of an “ex­cep­tion­al­ly po­tent an­ti­body” for Covid-19. Then the CEO, Hen­ry Ji …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz 

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times